Lexeo Therapeutics licenses full data and IP for LX2006 FA cardiomyopathy gene therapy from Cornell

Lexeo Therapeutics, Inc.

Upfront fees total $600,000; potential regulatory milestones up to $2.1M and commercial milestones up to $100M.
Exclusive license to patent rights and non-exclusive know-how for AAVrh.10hFXN (LX2006), including right to reference IND.
11 participants dosed across two trials (Lexeo's SUNRISE-FA and Weill Cornell Phase 1A); no treatment-related SAEs reported.
Interim clinical data readout expected mid-2024, combining data from both studies with up to 18-month follow-up.
LX2006 has FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations for FA cardiomyopathy.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Lexeo Therapeutics, Inc. entered into Third License Agreement with Cornell University valued at $600,000 (effective 2024-04-21).

Action: entry
Agreement: license
Counterparty: Cornell University
Value: $600,000
Effective: 2024-04-21

Exact text from the filing

On April 21, 2024, Lexeo Therapeutics, Inc. (the “Company”) entered into the Third License Agreement (the “License Agreement”) with Cornell University

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Lexeo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-046197

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.